Cargando…

Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study

OBJECTIVES: To evaluate the performance of individual biomarkers and a multi-biomarker disease activity (MBDA) score in the early rheumatoid arthritis (RA) patient population from the computer assisted management in early rheumatoid arthritis (CAMERA) study. METHODS: Twenty biomarkers were measured...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakker, Marije F, Cavet, Guy, Jacobs, Johannes WG, Bijlsma, Johannes W J, Haney, Douglas J, Shen, Yijing, Hesterberg, Lyndal K, Smith, Dustin R, Centola, Michael, van Roon, Joel A G, Lafeber, Floris P J G, Welsing, Paco M J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439649/
https://www.ncbi.nlm.nih.gov/pubmed/22596166
http://dx.doi.org/10.1136/annrheumdis-2011-200963
_version_ 1782243040366166016
author Bakker, Marije F
Cavet, Guy
Jacobs, Johannes WG
Bijlsma, Johannes W J
Haney, Douglas J
Shen, Yijing
Hesterberg, Lyndal K
Smith, Dustin R
Centola, Michael
van Roon, Joel A G
Lafeber, Floris P J G
Welsing, Paco M J
author_facet Bakker, Marije F
Cavet, Guy
Jacobs, Johannes WG
Bijlsma, Johannes W J
Haney, Douglas J
Shen, Yijing
Hesterberg, Lyndal K
Smith, Dustin R
Centola, Michael
van Roon, Joel A G
Lafeber, Floris P J G
Welsing, Paco M J
author_sort Bakker, Marije F
collection PubMed
description OBJECTIVES: To evaluate the performance of individual biomarkers and a multi-biomarker disease activity (MBDA) score in the early rheumatoid arthritis (RA) patient population from the computer assisted management in early rheumatoid arthritis (CAMERA) study. METHODS: Twenty biomarkers were measured in the CAMERA cohort, in which patients were treated with either intensive or conventional methotrexate-based treatment strategies. The MBDA score was calculated using the concentrations of 12 biomarkers (SAA, IL-6, TNF-RI, VEGF-A, MMP-1, YKL-40, MMP-3, EGF, VCAM-1, leptin, resistin and CRP) according to a previously trained algorithm. The performance of the scores was evaluated relative to clinical disease activity assessments. Change in MBDA score over time was assessed by paired Wilcoxon rank sum test. Logistic regression was used to evaluate the ability of disease activity measures to predict radiographic progression. RESULTS: The MBDA score had a significant correlation with the disease activity score based on 28 joints-C reactive protein (DAS28-CRP) (r=0.72; p<0.001) and an area under the receiver operating characteristic curve for distinguishing remission/low from moderate/high disease activity of 0.86 (p<0.001) using a DAS28-CRP cut-off of 2.7. In multivariate analysis the MBDA score, but not CRP, was an independent predictor of disease activity measures. Additionally, mean (SD) MBDA score decreased from 53 (18) at baseline to 39 (16) at 6 months in response to study therapy (p<0.0001). Neither MBDA score nor clinical variables were predictive of radiographic progression. CONCLUSIONS: This multi-biomarker test performed well in the assessment of disease activity in RA patients in the CAMERA study. Upon further validation, this test could be used to complement currently available disease activity measures and improve patient care and outcomes.
format Online
Article
Text
id pubmed-3439649
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-34396492012-09-12 Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study Bakker, Marije F Cavet, Guy Jacobs, Johannes WG Bijlsma, Johannes W J Haney, Douglas J Shen, Yijing Hesterberg, Lyndal K Smith, Dustin R Centola, Michael van Roon, Joel A G Lafeber, Floris P J G Welsing, Paco M J Ann Rheum Dis Clinical and Epidemiological Research OBJECTIVES: To evaluate the performance of individual biomarkers and a multi-biomarker disease activity (MBDA) score in the early rheumatoid arthritis (RA) patient population from the computer assisted management in early rheumatoid arthritis (CAMERA) study. METHODS: Twenty biomarkers were measured in the CAMERA cohort, in which patients were treated with either intensive or conventional methotrexate-based treatment strategies. The MBDA score was calculated using the concentrations of 12 biomarkers (SAA, IL-6, TNF-RI, VEGF-A, MMP-1, YKL-40, MMP-3, EGF, VCAM-1, leptin, resistin and CRP) according to a previously trained algorithm. The performance of the scores was evaluated relative to clinical disease activity assessments. Change in MBDA score over time was assessed by paired Wilcoxon rank sum test. Logistic regression was used to evaluate the ability of disease activity measures to predict radiographic progression. RESULTS: The MBDA score had a significant correlation with the disease activity score based on 28 joints-C reactive protein (DAS28-CRP) (r=0.72; p<0.001) and an area under the receiver operating characteristic curve for distinguishing remission/low from moderate/high disease activity of 0.86 (p<0.001) using a DAS28-CRP cut-off of 2.7. In multivariate analysis the MBDA score, but not CRP, was an independent predictor of disease activity measures. Additionally, mean (SD) MBDA score decreased from 53 (18) at baseline to 39 (16) at 6 months in response to study therapy (p<0.0001). Neither MBDA score nor clinical variables were predictive of radiographic progression. CONCLUSIONS: This multi-biomarker test performed well in the assessment of disease activity in RA patients in the CAMERA study. Upon further validation, this test could be used to complement currently available disease activity measures and improve patient care and outcomes. BMJ Group 2012-10 /pmc/articles/PMC3439649/ /pubmed/22596166 http://dx.doi.org/10.1136/annrheumdis-2011-200963 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode
spellingShingle Clinical and Epidemiological Research
Bakker, Marije F
Cavet, Guy
Jacobs, Johannes WG
Bijlsma, Johannes W J
Haney, Douglas J
Shen, Yijing
Hesterberg, Lyndal K
Smith, Dustin R
Centola, Michael
van Roon, Joel A G
Lafeber, Floris P J G
Welsing, Paco M J
Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study
title Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study
title_full Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study
title_fullStr Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study
title_full_unstemmed Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study
title_short Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study
title_sort performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the camera tight control study
topic Clinical and Epidemiological Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439649/
https://www.ncbi.nlm.nih.gov/pubmed/22596166
http://dx.doi.org/10.1136/annrheumdis-2011-200963
work_keys_str_mv AT bakkermarijef performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT cavetguy performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT jacobsjohanneswg performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT bijlsmajohanneswj performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT haneydouglasj performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT shenyijing performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT hesterberglyndalk performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT smithdustinr performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT centolamichael performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT vanroonjoelag performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT lafeberflorispjg performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy
AT welsingpacomj performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy